Actor Anthony Anderson is a comedian, but when it comes to diabetes, he is a serious advocate.
As CEO Emma Walmsley remakes the company's approach in emerging markets, GlaxoSmithKline will cut jobs in sub-Saharan Africa and rely on distributors.
Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past.
Pfizer is facing tough competition with Xalkori, and the latest move from England’s cost watchdogs isn’t making things any easier.
BI's Gilotrif is up against some stiff competition in the EGFR lung cancer space. But this week, it snagged a label update that will widen its reach.
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.
While Johnson & Johnson’s multiple myeloma drug Darzalex has steadily won new approvals from the FDA, it continues to face obstacles in England.
One of AbbVie's latest TV ads for IBD awareness doesn't use any words, but that hasn't stopped it from creating controversy.
GSK already partners with Vectura on respiratory therapies, but the British pharma giant could be looking to take the relationship one step further.
Good news for pharma's pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, a new analysis shows.